Thrivent Financial for Lutherans’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.7M | Buy |
105,375
+9,393
| +10% | +$1.27M | 0.03% | 508 |
|
|
2026
Q1 | $12.3M | Sell |
95,982
-41,881
| -30% | -$5.23M | 0.02% | 573 |
|
|
2025
Q4 | $16.8M | Buy |
137,863
+54,966
| +66% | +$6.3M | 0.03% | 506 |
|
|
2025
Q3 | $8.31M | Sell |
82,897
-53,047
| -39% | -$4.78M | 0.02% | 672 |
|
|
2025
Q2 | $11.3M | Buy |
135,944
+58,499
| +76% | +$4.67M | 0.02% | 520 |
|
|
2025
Q1 | $6.28M | Sell |
77,445
-367,355
| -83% | -$32.8M | 0.01% | 756 |
|
|
2024
Q4 | $40.1M | Sell |
444,800
-68,786
| -13% | -$6.66M | 0.08% | 317 |
|
|
2024
Q3 | $50.7M | Sell |
513,586
-100,779
| -16% | -$9.9M | 0.1% | 270 |
|
|
2024
Q2 | $57M | Sell |
614,365
-272,660
| -31% | -$24.4M | 0.11% | 229 |
|
|
2024
Q1 | $84.2M | Buy |
887,025
+327,143
| +58% | +$30.4M | 0.17% | 161 |
|
|
2023
Q4 | $50M | Sell |
559,882
-211,052
| -27% | -$15.7M | 0.11% | 254 |
|
|
2023
Q3 | $56.3M | Buy |
770,934
+534,853
| +227% | +$42.7M | 0.13% | 210 |
|
|
2023
Q2 | $19.6M | Buy |
236,081
+200,178
| +558% | +$16.7M | 0.04% | 435 |
|
|
2023
Q1 | $2.74M | Sell |
35,903
-378,883
| -91% | -$31.4M | 0.01% | 1088 |
|
|
2022
Q4 | $34.4M | Buy |
414,786
+379,787
| +1,085% | +$30.7M | 0.09% | 284 |
|
|
2022
Q3 | $2.78M | Sell |
34,999
-57,221
| -62% | -$4.82M | 0.01% | 1028 |
|
|
2022
Q2 | $6.85M | Sell |
92,220
-80,735
| -47% | -$6.06M | 0.02% | 726 |
|
|
2022
Q1 | $15.5M | Sell |
172,955
-411,281
| -70% | -$38M | 0.03% | 549 |
|
|
2021
Q4 | $65.4M | Sell |
584,236
-74,409
| -11% | -$8.97M | 0.13% | 206 |
|
|
2021
Q3 | $82.8M | Buy |
+658,645
| New | +$84.8M | 0.17% | 155 |
|
|
2021
Q1 | – | Sell |
-53,985
| Closed | -$7.6M | – | 2567 |
|
|
2020
Q4 | $7.6M | Buy |
+53,985
| New | +$6.91M | 0.02% | 722 |
|
|
2020
Q2 | – | Sell |
-103,484
| Closed | -$8.01M | – | 2307 |
|
|
2020
Q1 | $8.01M | Sell |
103,484
-103,432
| -50% | -$9.16M | 0.03% | 558 |
|
|
2019
Q4 | $19.7M | Buy |
206,916
+21,826
| +12% | +$1.89M | 0.06% | 389 |
|
|
2019
Q3 | $14.1M | Sell |
185,090
-82,406
| -31% | -$6.85M | 0.04% | 412 |
|
|
2019
Q2 | $23.5M | Buy |
267,496
+12,817
| +5% | +$1.09M | 0.07% | 304 |
|
|
2019
Q1 | $23.1M | Buy |
254,679
+19,796
| +8% | +$1.68M | 0.07% | 293 |
|
|
2018
Q4 | $16.9M | Sell |
234,883
-5,330
| -2% | -$429K | 0.06% | 333 |
|
|
2018
Q3 | $23M | Sell |
240,213
-27,765
| -10% | -$2.69M | 0.07% | 300 |
|
|
2018
Q2 | $25.5M | Buy |
267,978
+2,392
| +0.9% | +$220K | 0.08% | 248 |
|
|
2018
Q1 | $23.3M | Sell |
265,586
-51,514
| -16% | -$4.7M | 0.08% | 247 |
|
|
2017
Q4 | $26.9M | Sell |
317,100
-821
| -0.3% | -$68.8K | 0.09% | 212 |
|
|
2017
Q3 | $27.5M | Buy |
317,921
+141
| +0% | +$11.3K | 0.1% | 199 |
|
|
2017
Q2 | $24.5M | Hold |
317,780
| – | – | 0.1% | 195 |
|
|
2017
Q1 | $22M | Hold |
317,780
| – | – | 0.1% | 212 |
|
|
2016
Q4 | $18.8M | Sell |
317,780
-710
| -0.2% | -$43.8K | 0.08% | 248 |
|
|
2016
Q3 | $21.1M | Buy |
318,490
+52,010
| +20% | +$3.22M | 0.1% | 215 |
|
|
2016
Q2 | $14.4M | Buy |
266,480
+75,660
| +40% | +$4.15M | 0.07% | 279 |
|
|
2016
Q1 | $9.86M | Buy |
190,820
+84,620
| +80% | +$4.4M | 0.05% | 362 |
|
|
2015
Q4 | $7.46M | Buy |
106,200
+62,400
| +142% | +$4.26M | 0.04% | 435 |
|
|
2015
Q3 | $2.73M | Buy |
+43,800
| New | +$3.45M | 0.01% | 717 |
|
|
2014
Q1 | – | Sell |
-282,360
| Closed | -$12.3M | – | 1589 |
|
|
2013
Q4 | $12.3M | Sell |
282,360
-2,340
| -0.8% | -$96.9K | 0.07% | 272 |
|
|
2013
Q3 | $12.3M | Buy |
+284,700
| New | +$11.5M | 0.08% | 271 |
|
Other funds holding XBI
JFG
Thrivent Financial for Lutherans's XBI Position: Q2 2026 in Review
Thrivent Financial for Lutherans increased its State Street SPDR S&P Biotech ETF (XBI) stake by 9.8% in Q2 2026, buying an estimated $1.27M and bringing the position to 105,375 shares worth $16.7M. The position accounts for 0.03% of the portfolio, ranked #508.
Thrivent Financial for Lutherans first reported a position in XBI in Q3 2013 and has held it in 42 quarters since. The position peaked at $84.2M in Q1 2024. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Thrivent Financial for Lutherans held 105,375 shares of State Street SPDR S&P Biotech ETF worth $16.7M as of Q2 2026.
- Thrivent Financial for Lutherans bought 9,393 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.27M.
- State Street SPDR S&P Biotech ETF made up 0.03% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #508 holding.
- Thrivent Financial for Lutherans first reported a position in State Street SPDR S&P Biotech ETF in Q3 2013 and has held it in 42 quarters since.
- Thrivent Financial for Lutherans's State Street SPDR S&P Biotech ETF position peaked at $84.2M in Q1 2024.
- 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.